WSO - March 2024 - 267

Kim et al.
267
National Acute Stroke Program. J Neurointerv Surg 2020;
12: 574-578.
30. Alet M, Lucci FR and Ameriso S. Mechanical thrombectomy
for reperfusion of acute ischemic stroke in a Stroke
Unit in Argentina. Arq Neuropsiquiatr 2020; 78: 39-43.
31. Do Rosário CF, Fernandes Neto WG, Pessotti AL, et al.
Epidemiological analysis of stroke patients with emphasis
on access to acute-phase therapies. Arq Neuropsiquiatr
2022; 80: 117-124.
32. Brunser AM, Mazzon E, Cavada G, et al. Low dosis of
alteplase, for ischemic stroke after Enchanted and its determinants,
a single center experience. Arq Neuropsiquiatr
2020; 78: 681-686.
33. Gil-Rojas Y and Lasalvia P. Budgetary impact analysis
of alteplase-recombinant tissue plasminogen activator
(rtPA)-as a thrombolytic treatment for acute ischemic
stroke in Colombia. Expert Rev Pharmacoecon Outcomes
Res 2022; 22: 1095-1102.
34. Gonzalez-Aquines A, Cordero-Pérez AC, Cristobal-Niño
M, Pérez-Vázquez G and Góngora-Rivera F; GECEN
Investigators. Contribution of onset-to-alarm time to prehospital
delay in patients with ischemic stroke. J Stroke
Cerebrovasc Dis 2019; 28: 104331.
35. Abanto C, Valencia A, Calle P, et al. Challenges of thrombolysis
in a developing country: characteristics and outcomes
in Peru. J Stroke Cerebrovasc Dis 2020; 29: 104819.
36. Aref H, Zakaria M, Shokri H, Roushdy T, El Basiouny A
and El Nahas N. Changing the landscape of stroke in Egypt.
Cerebrovasc Dis Extra 2021; 11: 155-159.
37. Khazaei M, Davoodian A, Taheri M and Ghafouri-Fard S.
Former antiplatelet drug administration and consequences
of intravenous thrombolysis in acute ischemic stroke. Hum
Antibodies 2020; 28: 53-56.
38. Acherqui M, Khattab H, Habtany Y, et al. Assessment of eligibility
for thrombolysis in acute ischaemic stroke patients
in Morocco. Pan Afr Med J 2020; 36: 351.
39. Al Harthi HA, Al Kashmiri A, Zakaryia LM, et al. Clinical
profile of stroke patients presenting to the Emergency
Department of a Major Stroke Centre in Oman. Sultan
Qaboos Univ Med J 2022; 22: 91-97.
40. Ibrahim F, Deleu D, Akhtar N, et al. Burden of stroke in
qatar. J Stroke Cerebrovasc Dis 2015; 24(12): 2875-2879.
41. Al Khathaami AM, Al Bdah B, Tarawneh M, et al.
Utilization of intravenous tissue plasminogen activator and
reasons for nonuse in acute ischemic stroke in Saudi Arabia.
J Stroke Cerebrovasc Dis 2020; 29: 104761.
42. Kömürcü HF, Gözke E, Doğan Ak P, Aslan IK, Salt I and
Bi Er ÇİÖ. Changes in neutrophil, lymphocyte, platelet
ratios and their relationship with NIHSS after rtPA and/or
thrombectomy in ischemic stroke. J Stroke Cerebrovasc Dis
2020; 29: 105004.
43. Hasan ATMH, Das SC, Islam MS, et al. Impact of COVID19
on hospital admission of acute stroke patients in
Bangladesh. PLoS One 2021; 16: e0240385.
44. Mathew T, John SK, Sarma G, et al. COVID-19-related
strokes are associated with increased mortality and morbidity:
a multicenter comparative study from Bengaluru, South
India. Int J Stroke 2021; 16: 429-436.
45. Nepal G, Yadav JK, Basnet B, Shrestha TM, Kharel G
and Ojha R. Status of prehospital delay and intravenous
thrombolysis in the management of acute ischemic stroke
in Nepal. BMC Neurol 2019; 19: 155.
46. Zaman Babar MU, Khan AZ, Hakim H, Gilani J and Wasay
M. Utilization and outcomes with low dose tissue plasminogen
activator as intravenous thrombolytic therapy for
ischaemic stroke at Aga Khan University Hospital, Karachi:
a retrospective analysis. J Pak Med Assoc 2019; 69: 1705-
1710.
47. Mesiano T, Kurniawan M, Saputri KM, et al. Endovascular
treatment in acute ischemic stroke adoption and practice:
a single-center Indonesian experience. Cerebrovasc Dis
Extra 2021; 11: 72-76.
48. Aziz ZA and Sidek NN. Annual report of the Malaysian
stroke registry 2009-2016. Kuala Terengganu, Malaysia:
Clinical Research Centre, 2017.
49. Navarro JC, San Jose MC, Collantes E, et al. Stroke
thrombolysis in the Philippines. Neurol Asia 2018; 23:
115-120.
50. Herath HMM, Rodrigo C, Alahakoon A, et al. Outcomes of
stroke patients undergoing thrombolysis in Sri Lanka; an
observational prospective study from a low-middle income
country. BMC Neurol 2021; 21: 434.
51. Tiamkao S, Ienghong K, Cheung LW, Celebi I, Suzuki T
and Apiratwarakul K. Stroke incidence, rate of thrombolytic
therapy, mortality in Thailand from 2009 to 2021.
Open Access Maced J Med Sci 2022; 9: 110-115.
52. Mai DT, Dao XC, Luong NK, Nguyen TK, Nguyen HT and
Nguyen TN. Current state of stroke care in Vietnam. Stroke:
Vasc Interv Neurol 2022; 2: e000331.
53. Ohnmar Kyaw M, Shew ZM, et al. The pattern and burden
of neurological disorders: a systemic review of Neurology
Department, Yangon General Hospital, Myanmar. Neurol
Asia 2020; 25: 555-561.
54. Venketasubramanian N, Khine YM, Ohnmar O, Khin MPPK
and Win MT. Burden of stroke in Myanmar. Cerebrovasc
Dis Extra 2021; 11: 49-51.
55. Arabambi B, Oshinaike O, Ogun SA, et al. Stroke units in
Nigeria: a report from a nationwide organizational crosssectional
survey. Pan Afr Med J 2022; 42: 140.
56. Mandizvidza V, London L and Bryer A. Shortfall in stroke
care: a study of ischaemic stroke care practices in a South
African metropole. S Afr Med J 2021; 111: 215-219.
57. Marko M, Posekany A, Szabo S, et al. Trends of r-tPA
(Recombinant Tissue-Type Plasminogen Activator) treatment
and treatment-influencing factors in acute ischemic
stroke. Stroke 2020; 51: 1240-1247.
58. Vanhoucke J, Hemelsoet D, Achten E, et al. Impact of
a code stroke protocol on the door-to-needle time for IV
thrombolysis: a feasibility study. Acta Clin Belg 2020; 75:
267-274.
59. Varjoranta T, Raatiniemi L, Majamaa K, Martikainen M and
Liisanantti JH. Prehospital and hospital delays for stroke
patients treated with thrombolysis: a retrospective study
from mixed rural-urban area in Northern Finland. Australas
Emerg Care 2019; 22: 76-80.
60. Olié V, Grave C, Tuppin P, Duloquin G, Béjot Y and Gabet
A. Patients hospitalized for ischemic stroke and intracerebral
hemorrhage in France: time trends (2008-2019),
in-hospital outcomes, age and sex differences. J Clin Med
2022; 11: 1669.
International Journal of Stroke, 19(3)

WSO - March 2024

Table of Contents for the Digital Edition of WSO - March 2024

Contents
WSO - March 2024 - Cover1
WSO - March 2024 - Cover2
WSO - March 2024 - 245
WSO - March 2024 - Contents
WSO - March 2024 - 247
WSO - March 2024 - 248
WSO - March 2024 - 249
WSO - March 2024 - 250
WSO - March 2024 - 251
WSO - March 2024 - 252
WSO - March 2024 - 253
WSO - March 2024 - 254
WSO - March 2024 - 255
WSO - March 2024 - 256
WSO - March 2024 - 257
WSO - March 2024 - 258
WSO - March 2024 - 259
WSO - March 2024 - 260
WSO - March 2024 - 261
WSO - March 2024 - 262
WSO - March 2024 - 263
WSO - March 2024 - 264
WSO - March 2024 - 265
WSO - March 2024 - 266
WSO - March 2024 - 267
WSO - March 2024 - 268
WSO - March 2024 - 269
WSO - March 2024 - 270
WSO - March 2024 - 271
WSO - March 2024 - 272
WSO - March 2024 - 273
WSO - March 2024 - 274
WSO - March 2024 - 275
WSO - March 2024 - 276
WSO - March 2024 - 277
WSO - March 2024 - 278
WSO - March 2024 - 279
WSO - March 2024 - 280
WSO - March 2024 - 281
WSO - March 2024 - 282
WSO - March 2024 - 283
WSO - March 2024 - 284
WSO - March 2024 - 285
WSO - March 2024 - 286
WSO - March 2024 - 287
WSO - March 2024 - 288
WSO - March 2024 - 289
WSO - March 2024 - 290
WSO - March 2024 - 291
WSO - March 2024 - 292
WSO - March 2024 - 293
WSO - March 2024 - 294
WSO - March 2024 - 295
WSO - March 2024 - 296
WSO - March 2024 - 297
WSO - March 2024 - 298
WSO - March 2024 - 299
WSO - March 2024 - 300
WSO - March 2024 - 301
WSO - March 2024 - 302
WSO - March 2024 - 303
WSO - March 2024 - 304
WSO - March 2024 - 305
WSO - March 2024 - 306
WSO - March 2024 - 307
WSO - March 2024 - 308
WSO - March 2024 - 309
WSO - March 2024 - 310
WSO - March 2024 - 311
WSO - March 2024 - 312
WSO - March 2024 - 313
WSO - March 2024 - 314
WSO - March 2024 - 315
WSO - March 2024 - 316
WSO - March 2024 - 317
WSO - March 2024 - 318
WSO - March 2024 - 319
WSO - March 2024 - 320
WSO - March 2024 - 321
WSO - March 2024 - 322
WSO - March 2024 - 323
WSO - March 2024 - 324
WSO - March 2024 - 325
WSO - March 2024 - 326
WSO - March 2024 - 327
WSO - March 2024 - 328
WSO - March 2024 - 329
WSO - March 2024 - 330
WSO - March 2024 - 331
WSO - March 2024 - 332
WSO - March 2024 - 333
WSO - March 2024 - 334
WSO - March 2024 - 335
WSO - March 2024 - 336
WSO - March 2024 - 337
WSO - March 2024 - 338
WSO - March 2024 - 339
WSO - March 2024 - 340
WSO - March 2024 - 341
WSO - March 2024 - 342
WSO - March 2024 - 343
WSO - March 2024 - 344
WSO - March 2024 - 345
WSO - March 2024 - 346
WSO - March 2024 - 347
WSO - March 2024 - 348
WSO - March 2024 - 349
WSO - March 2024 - 350
WSO - March 2024 - 351
WSO - March 2024 - 352
WSO - March 2024 - 353
WSO - March 2024 - 354
WSO - March 2024 - 355
WSO - March 2024 - 356
WSO - March 2024 - 357
WSO - March 2024 - 358
WSO - March 2024 - 359
WSO - March 2024 - 360
WSO - March 2024 - 361
WSO - March 2024 - 362
WSO - March 2024 - 363
WSO - March 2024 - 364
WSO - March 2024 - 365
WSO - March 2024 - 366
WSO - March 2024 - 367
WSO - March 2024 - 368
WSO - March 2024 - 369
WSO - March 2024 - 370
WSO - March 2024 - 371
WSO - March 2024 - 372
WSO - March 2024 - Cover3
WSO - March 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com